The drug works by activating a protein called procaspase-3 that triggers cell death. Vanquish's small molecule therefore is aimed at kicking off the process of apoptosis in cancer cells, ultimately killing them.
Learning how apoptosis works – that is, the programmed death of a cell – could play an important role in helping researchers understand how debilitating diseases work – or even how to make drugs more effective. SEED Partners just acquired the patents for a fluorescent dye test that tracks, in vivo, cell death. The Minneapolis-based holding now holds rights to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.